LGND News and Press, Ligand Pharmaceuticals Incorporated From 10/10/21

Ligand has a cornucopia of productive assets. Ligand has one cash cow, Captisol, that has been generating outsized revenues. Gilead is an important Captisol customer using Captisol in its remdesivir, an asset with an uncertain future. Shareholders can take heart that Liga...

A list of 62 recent IPOs debuted on The Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 reconstitution. Following up on our previous article on recently-IPOd biotech stocks joining the index, in this article, we discuss another four biotechs ma...

Digital Turbine (NASDAQ: APPS) , the leading independent mobile growth platform that supercharges advertising and monetization, was featured in this week’s Simply Wall St Journal. The piece, which also discusses The Kroger Company (NYSE: KR) and Walmart Inc. (NYSE: WMT) , offers...

Performance Food Group & Digital Turbine Set to Join S&P MidCap 400; TreeHouse Foods & Ligand Pharmaceuticals to Join S&P SmallCap 600 Performance Food Group & Digital Turbine Set to Join S&P MidCap 400; TreeHouse Foods & Ligand Pharmaceuticals to Joi...

First regulatory approval of an OmniAb-derived antibody Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China’s National Medical Products Administration (NMPA) for zimber...

Sparsentan treatment demonstrated a statistically significant mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator irbesartan (p<0.0001) Sparsentan has been generally well-tolerated and consistent with the previo...

COLUMBUS, Ohio, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it has completed enrollment in its Phase 2 r...

Image source: The Motley Fool. Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) Q2 2021 Earnings Call Jul 29, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Ligand Pharmaceuticals Incorporated (LGND) Q2 2021 Earn...

Ligand Pharmaceuticals Incorporated (LGND) Q2 2021 Earnings Conference Call July 29, 2021 04:30 PM ET Company Participants Simon Latimer - Head of IR John Higgins - CEO Matthew Korenberg - CFO Matt Foehr - COO Matthew Foehr - Conference Call Participants Lawrence Solow - CJS Securities Matt H...

Ligand Pharmaceuticals (NASDAQ:LGND): Q2 Non-GAAP EPS of $1.63 beats by $0.27; GAAP EPS of $1.79 beats by $1.05. Revenue of $84.7M (+104.5% Y/Y) beats by $13.29M. Ligand now expects full-year 2021 total revenues to be between $265 million and $275 million (prior $291 million) vs. consensus of...